GLP1R and type 2 diabetes mellitus: The long-acting incretin mimetic liraglutide, an agonist of glucagon-like peptide-1 receptors, is extensively studied not only as a treatment option for type 2 diabetes, obesity, and related complications [14], but also for type 1 diabetes [15].